Incidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in Italy (Q33501862)

27 July 2017

Incidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in Italy (English)

1 reference

27 July 2017

0 references

0 references

1 reference

Patrizio Pezzotti

1

1 reference

27 July 2017

Jessica Mantovani

2

1 reference

27 July 2017

Nicoletta Benincori

3

1 reference

27 July 2017

Eleonora Mucchino

4

1 reference

27 July 2017

Domenico Di Lallo

5

1 reference

27 July 2017

10 September 2009

1 reference

27 July 2017

1 reference

27 July 2017

9

1 reference

27 July 2017

56

1 reference

Creative Commons Attribution 2.0 Generic

27 July 2017

start time

10 September 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

exact match

https://scigraph.springernature.com/pub.10.1186/1471-2431-9-56

0 references

cites work

Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749027

Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749027

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

21 June 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749027

21 June 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749027

Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749027

Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749027

Bronchiolitis and asthma in infancy and early childhood

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749027

The quality of the data on the certificate of delivery care

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749027

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2431-9-56

National disease burden of respiratory viruses detected in children by polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2431-9-56

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2431-9-56

Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2431-9-56

Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2431-9-56

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2431-9-56

Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2431-9-56

The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2431-9-56

Determinants of hospitalization in a cohort of chronic dialysis patients in central Italy

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2749027

Methodology Used for “Software for Automated Linkage in Italy” (SALI)

31 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2431-9-56

[The birth certificate as an instrument for pregnancy]

21 January 2018

1 reference

12 December 2020

Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn

1 reference

12 December 2020

Use of palivizumab in children with congenital heart disease

1 reference

12 December 2020

Palivizumab efficacy in preterm infants with gestational age ≤30 weeks without bronchopulmonary dysplasia

1 reference

12 December 2020

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group

1 reference

12 December 2020

Hospitalizations for pediatric anaphylaxis

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2431-9-56

1 reference

Dimensions Publication ID

27 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2431-9-56

9 September 2019

1 reference

27 July 2017

1 reference